On Tuesdady, Johnson & Johnson JNJ 1.04% and Achillion Pharmaceuticals, Inc. ACHN 1.32% announced this week that they are entering into a collaboration agreement to develop one or more of Achillion’s lead hepatitis C virus (HCV) treatments, including ACH-3102, ACH-3422 and sovaprevir.
Shares of Achillion fell nearly 15 percent on Wednesday as shareholders were disappointed by the terms of the deal.
Deutsche Bank analysts released a report on Tuesday breaking down the deal and what it means for other players in the HCV space. Here’s what they had to say.
Impact On Other HCV Names
According to the report, Deutsche Bank is not making any changes to its forecasts for Gilead Sciences, Inc. GILD 0.44% or AbbVie Inc ABBV 0.26% based on the Johnson & Johnson/Achillion deal. Deutsche Bank already accounted for competition in their models for the two stocks, and stated that “this deal does not change our numbers.”
Market Share Projections
Deutsche Bank is projecting long-term market share in the HCV market of…
Read the rest of this article (and all my other articles) for free on Benzinga by clicking here
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!